Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.50 |
| ▸ | ITGAV | P06756 | 4/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 11/20 | 0.48 |
| ▸ | MC5R | P33032 | 11/20 | 0.48 |
| ▸ | MC3R | P41968 | 11/20 | 0.48 |
| ▸ | MC1R | Q01726 | 11/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462935 | 0.94 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL14883291 | 0.92 | MC4R (0.49) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL10138534 | 0.91 | ITGB3 (0.60) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL15397366 | 0.91 | ITGB3 (0.60) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL10170032 | 0.91 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL19365170 | 0.90 | ITGB3 (0.47) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL24975502 | 0.90 | PIN1 (0.49) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL22872754 | 0.89 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL10000329 | 0.88 | CACNA1B (0.49) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL15853554 | 0.88 | MC4R (0.46) | ITGB3ITGAVITGB1ITGA5MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8066824-B2 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | ITGB3 12/4885ITGAV 24/4885ITGB1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.